ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
ADC Therapeutics SA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.44+0.04 (+2.86%)
Close on Oct 19, 2026
- Market cap
- $223.22M
- P/E (TTM)
- –
- Dividend yield
- –
ADC Therapeutics SA revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenues, net | $18.63M | $20.03M | $22.31M | $15.75M | $18.09M | $17.40M | $16.39M | $18.02M | $17.03M | $17.85M | $16.64M | $14.27M | 96.8% | +3.0% |
| Royalties | $614.00K | $818.00K | $746.00K | $677.00K | $754.00K | $629.00K | $524.00K | $448.00K | $380.00K | $205.00K | $147.00K | $226.00K | 3.2% | -18.6% |
| License revenues | $0 | $0 | $0 | $0 | $0 | $5.00M | $0 | $0 | $0 | $0 | – | – | 0.0% | – |
| Product revenues, net | – | – | – | – | – | – | – | – | – | – | – | $14.27M | – | – |
| License revenues and royalties | – | – | – | – | – | – | – | – | – | – | – | $0 | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $18.63M | $20.03M | $22.31M | $15.75M | $18.09M | $17.40M | $16.39M | $18.02M | $17.03M | $17.85M | $16.64M | $14.27M | 96.8% | +3.0% |
| EMEA | $614.00K | $818.00K | $746.00K | $677.00K | $754.00K | $5.63M | $524.00K | $448.00K | $380.00K | $205.00K | $147.00K | $226.00K | 3.2% | -18.6% |
| Japan | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
From the segment and revenue-disaggregation notes of ADC Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.